



Salzburg
Cancer
Research
Institute

SALZBURG BREAST CANCER TALK 02. – 03.03.2018

MASTERING TRANSLATIONAL IMMUNO-ONCOLOGY

FRIDAY, 2nd MARCH

13:00 – 14:00 Come together and Lunch Buffet

14:00 Welcome and introduction

14:10 Current evidence of immunotherapy in breast cancer

Richard Greil (*Salzburg*)

Peter Schmid (*London*)

14:30–16:00 Immunogenicity I: Tumour - immune cell interaction

Chair: Richard Greil (Salzburg), Karen Willard-Gallo (Brussels)

14:30 The role of B-cells and Tertiary Lymphoid Structures (TLS)

Karen Willard-Gallo (*Brussels*)

14:50 The yin yang of innate immunity, inflammation and cancer

Alberto Mantovani (*Milan*)

15:10 Computing and probing cancer immunity

Zlatko Trajanoski (*Innsbruck*)

15:30 Panel discussion

16:00 – 16:30 Coffee break

16:30 – 18:00 Immunogenicity II: Triggers and Modulators

Chair: Fabrice André (Paris), Richard D. Kennedy (Belfast)

16:30 Influence on immunogenicity by driver mutations

Fabrice André (*Paris*)

16:50 Influence on immunogenicity by the microbiota

Maria Rescigno (*Milan*)

17:10 Influence on immunogenicity by DNA damage response deficiency

Richard D. Kennedy (*Belfast*)

17:30 Panel discussion

18:30 Dinner

SATURDAY, 3rd MARCH

08:30 – 10:00 Monitoring and prediction of response to immunotherapy

Chair: Fritz Aberger (Salzburg), Gabriel Rinnerthaler (Salzburg)

08:30 Prediction of response to PD-1/PD-L1 blockade*

Marleen Kok (*Amsterdam*)

09:00 Change of immune infiltrate during treatment*

Roberto Salgado (*Brussels*)

09:30 Monitoring anti-tumor immune response in the blood*

Alexander Egle (*Salzburg*)

10:00 Neoantigene heterogeneity*

Marco Gerlinger (*London*)

10:30 – 11:00 Coffee break

11:00 – 12:30 Combination strategies with checkpoint-inhibitors

Chair: Richard Greil (Salzburg), Simon Gampenrieder (Salzburg)

11:00 Combination with chemotherapy

Giuseppe Curigliano (*Milan*)

11:20 Combination with vaccination

Richard Greil (*Salzburg*)

11:40 Combination with radiotherapy

Udo Gaipl (*Erlangen*)

12:00 Panel discussion

12:30 Lunch Buffet

* Discussion after lecture

The Pitter Event Center
Rainerstrasse 6 – 8
5020 Salzburg

www.imlauer.com



Free WLAN-Access:
Pitter Event Center
PW: pitter18



Prof. Dr. Richard Greil
Head of the IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Prof. Maria Rescigno PhD
Full Professor
Head, Mucosal Immunology
and microbiota Unit
Humanitas University
Milan, Italy

Priv.-Doz. Dr. Alexander Egle
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Prof. Peter Schmid FRCP MD PhD
Centre Lead, Centre for Experimental
Cancer Medicine
Director, Breast Cancer, St Bartholomew
Hospital London
London, United Kingdom

Prof. Richard Kennedy MD PhD
McClay Professor of Medical Oncology
Queen's University of Belfast
Global VP and Medical Director Almac Diagnostics

Marco Gerlinger MD FRCP
Medical Oncologist and Research Group Leader
Translational Oncogenomics Laboratory
Centre for Evolution and Cancer
Institute of Cancer Research
London, United Kingdom

Karen Willard-Gallo MD PhD
Head, Molecular Immunology Laboratory
Institut Jules Bordet
Université Libre de Bruxelles
Brussels, Belgium

Prof. Dr. Fritz Aberger
Molecular Cancer and Stem Cell Research
Lab Department of Molecular Biology
University of Salzburg
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Dr. Simon P. Gampenrieder
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Prof. Alberto Mantovani MD
Humanitas University
Scientific Director
Istituto Clinico Humanitas IRCCS
Milan, Italy

Dr. Gabriel Rinnerthaler
IIIrd Medical Department
University Hospital Salzburg
Paracelsus Medical University
Salzburg Cancer Research Institute (SCRI)
Cancer Cluster Salzburg (CCS)
Salzburg, Austria

Giuseppe Curigliano MD PhD
University of Milan
Director, New Drugs and
Early Drug Development for
Innovative Therapies Division
European Institute of Oncology
Milan, Italy

Prof. Dipl.-Ing. Dr. Zlatko Trajanoski
Biocenter, Division for Bioinformatics
Medical University of Innsbruck
Innsbruck, Austria

Marleen Kok MD PhD
Medical Oncologist and Research Fellow
Cancer Immunotherapy of the Dutch Cancer Society
The Netherlands Cancer Institute
Amsterdam, the Netherlands

Prof. Dr. Udo Gaipl
Head of Radiation Immunobiology
Universitätsklinikum Erlangen
Department of Radiation Oncology
Erlangen, Germany

Prof. Fabrice André MD PhD
Research Director, Head of INSERM
Unit U981
Institut Gustave Roussy
Department of Medical Oncology
Villejuif, France

Dr. Roberto Salgado
Breast Cancer Translational Research Laboratory
Department of Pathology, GZA
Institut Jules Bordet, Brussels
Antwerp, Belgium

Organization:
Richard Greil
Gabriel Rinnerthaler
Simon P. Gampenrieder

Salzburg Cancer Research Institute (SCRI) with
Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR)
www.limcr.at and
Center for Clinical Cancer and Immunology Trials (SCRI-CCIT)
www.cccit.at

in cooperation with the
Cancer Cluster Salzburg | www.cancercluster-salzburg.at and **AGMT gemeinnützige GmbH** | www.agmt.at



Salzburg
Cancer
Research
Institute

CCIT
Center for
Clinical Cancer
and Immunology Trials

LIMCR
Laboratory for
Immunological and
Molecular Cancer Research



CANCER
CLUSTER
SALZBURG
WWW.CANCERCLUSTER-SALZBURG.AT

AGMT

ARBEITSGEMEINSCHAFT
MEDIKAMENTÖSE
TUMORTHERAPIE

Kindly supported by:      

This event has been approved for
12 DFP points